[go: up one dir, main page]

CO5180536A1 - CATEPSIN PROTEASE INHIBITORS - Google Patents

CATEPSIN PROTEASE INHIBITORS

Info

Publication number
CO5180536A1
CO5180536A1 CO00023372A CO00023372A CO5180536A1 CO 5180536 A1 CO5180536 A1 CO 5180536A1 CO 00023372 A CO00023372 A CO 00023372A CO 00023372 A CO00023372 A CO 00023372A CO 5180536 A1 CO5180536 A1 CO 5180536A1
Authority
CO
Colombia
Prior art keywords
alkyl
group
het
alkenyl
catepsin
Prior art date
Application number
CO00023372A
Other languages
Spanish (es)
Inventor
Dennis Shinji Yamashita
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5180536A1 publication Critical patent/CO5180536A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/12—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de Fórmula I: <EMI FILE="00023372_1" ID="1" IMF=JPEG >en la cual: R1 se selecciona del grupo constituido por: R", R"C(O), R"C(S), R"SO2, R"OC(O), R"R´NC(O), y R"OC(O)NR´CH(R6)C(O);R2 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R3 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquiloC0-6, Ar-alquilo C0-6, y Het-alquilo C0-6;R4 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6;R5 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R6 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6;R7 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, cicloalquil C3-6, -alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6; R8 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, cicloalquil C3-6 -alquilo C0-6, Ar-alquilo C0-6, y Het-alquilo C0-6;R´ se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R" se selecciona del grupo constituido por: alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6, Ar-alquenilo C2-6 y Hetalquenilo C2-6;X se selecciona del grupo constituido por: 0 y S; e Y se selecciona del grupo constituido por: 0 y S; y sus sales, hidratos y solvatos farmacéuticamente aceptables.A compound of Formula I: <EMI FILE = "00023372_1" ID = "1" MFI = JPEG> in which: R1 is selected from the group consisting of: R ", R" C (O), R "C (S) , R "SO2, R" OC (O), R "R´NC (O), and R" OC (O) NR´CH (R6) C (O); R2 is selected from the group consisting of: H, alkyl C1-6, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R3 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl C3-6-C0-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R4 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R5 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R6 is selected from the group consisting of : H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl and Het-C0-6 alkyl; R7 is selected from the group consisting of: H, C1- alkyl 6, C2-6 alkenyl, C3-6 cycloalkyl, C0-6 alkyl, Ar-C0-6 alkyl and Het-C0-6 alkyl; R8 was selected a of the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R 'is selected from the group consisting by: H, C1-6 alkyl, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R "is selected from the group consisting of: C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, Ar2-6 alkenyl and C2-6 hetalkenyl; X is selected from the group consisting of: 0 and S; and Y is selected from the group consisting of: 0 and S; and its pharmaceutically acceptable salts, hydrates and solvates.

CO00023372A 1999-03-31 2000-03-31 CATEPSIN PROTEASE INHIBITORS CO5180536A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12725099P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
CO5180536A1 true CO5180536A1 (en) 2002-07-30

Family

ID=22429122

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00023372A CO5180536A1 (en) 1999-03-31 2000-03-31 CATEPSIN PROTEASE INHIBITORS

Country Status (8)

Country Link
EP (1) EP1173429A4 (en)
JP (1) JP2002540199A (en)
AU (1) AU4066900A (en)
CO (1) CO5180536A1 (en)
HK (1) HK1044758A1 (en)
PE (1) PE20001607A1 (en)
UY (1) UY26088A1 (en)
WO (1) WO2000058296A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
EP1232155A4 (en) 1999-11-10 2002-11-20 Smithkline Beecham Corp Protease inhibitors
CZ20023168A3 (en) 2000-03-21 2003-02-12 Smithkline Beecham Corporation Protease inhibitors
JP2005515254A (en) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション Cycloalkylketoamide derivatives useful as cathepsin K inhibitors
JP2004196696A (en) * 2002-12-18 2004-07-15 Kyowa Hakko Kogyo Co Ltd Prophylactic or therapeutic agent for arthritis
CN113651795B (en) * 2021-09-14 2022-09-02 江西开源香料有限公司 Synthesis method of watermelon ketone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use

Also Published As

Publication number Publication date
JP2002540199A (en) 2002-11-26
AU4066900A (en) 2000-10-16
PE20001607A1 (en) 2001-03-07
WO2000058296A1 (en) 2000-10-05
HK1044758A1 (en) 2002-11-01
EP1173429A4 (en) 2002-06-19
EP1173429A1 (en) 2002-01-23
UY26088A1 (en) 2000-10-31

Similar Documents

Publication Publication Date Title
NO20013379L (en) 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
AR006720A1 (en) A COMPOUND DERIVED FROM HETERO-CYCLIC AZAHEXANE, ITS USE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, PROCEDURE FOR PREPARING IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
DE60135764D1 (en) NITROGENIC, FIVE-GLASS RING COMPOUNDS
AR240929A2 (en) N-pyridinsulphonyl-n&lt;&lt;&#39;-pyridinyl and -triazinyl ureas: process for the preparation thereof, intermediates for exclusive use in said process and compositions that contain said ureas
CO5200785A1 (en) THERAPEUTIC USE OF QUINAZOLINE
CO5550421A2 (en) INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASE
AR047076A1 (en) PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS
DE69923692D1 (en) GROWTH HORMONE RELEASING OXINDOL DERIVATIVES
FI883669A0 (en) 1 - / (4-PIPERIDINYL) METHYL / -1,2,3,4-TETRAHYDRO-9H-PYRIDO / 3.4-B / INDOLDERIVAT, DERAS FRAMSTAELLNING OCH TERAPEUTISKA ANVAENDNING.
CO5180629A1 (en) PYRIMIDINE-2,4,6-METALOPROTEINASE INHIBITING TTRIONS
CO5261565A1 (en) INHIBITORS OF N- (5 - (((5-RENT-2-OXAZOLIL) METHYL) TIO) -2-TIAZOLIL) -CARBOXAMIDE OF CYCLINE DEPENDENT KINASES
BG103258A (en) Azinyloxy- and phenoxydiaryl derivatives of carboxylic acids, their preparation and application as mixed eta/etb endothelin-receptor antagonists
CO5180536A1 (en) CATEPSIN PROTEASE INHIBITORS
TW200505446A (en) Inhibitor of cox
DE60121587D1 (en) CYCLIC GMP SPECIFIC PHOSPHODIESTERASE INHIBITORS
CO5271679A1 (en) PROTEASA INHIBITORS 7-14 MEMBERS
EA200101230A1 (en) NEW INHIBITORS OF METALLOPROTEASIS, THEIR METHOD OF OBTAINING AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
CO5180541A1 (en) PROTEASE INHIBITORS OF THE 1,3-DIAMINOCETONE TYPE WITH 8-14 MEMBER RING
EA200400666A3 (en) New benzothiazine and benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
KR970706280A (en) Bicyclic carboxamides as 5-HT1 antagonists
CO5080787A1 (en) ISOQUINOLINS
SV2001000050A (en) PHARMACEUTICAL COMPOUNDS CASE N.G. 1336
DK0435235T3 (en) New isoquinoline derivatives and salts thereof
CO5150177A1 (en) HYDRAZINE DERIVATIVES
TW200510300A (en) Amino alcohol compounds

Legal Events

Date Code Title Description
FA Application withdrawn